Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Visible Genetics Inc.(VGIN) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (171)	3/19/1998 11:21:00 AM
From: scaram(o)uche	Respond to of 337

Richard: A clear indication....... a preference for letting Amersham take care of the research market. Peter.... I'll try to answer some of your questions a bit later. MURXF........ expands the market, doesn't cover protease inhibitors..... the Abbott deal will force other players to consider alliances? What's the latest on the durability of a successful switch, crix -----> nelf? Rick

To: Richard Haugland who wrote (171)	3/19/1998 1:03:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 337

These are the numbers of systems reported before the Amersham annoucement. The fourth quarter 1997 sales include direct VGI sales of 43 OpenGene Systems and 5 additional OpenGene systems shipped as part of partnership projects. In addition, VGI received orders from customers and distributors for a further 51 systems that will be shipped in the first quarter 1998. ''At the end of 1997, Visible Genetics had 97 installed sites with a total of over 138 systems in the field. We are very pleased with our fourth quarter results and continued quarterly growth. Since the VGINF announcement today says that the 100 units to Amersham "represent the first portion of a minimum order" it seems that between installed sites and new ones that the number of units in the field will double, with a good increase in number of kits too.